Rokit Healthcare recorded a daily limit gain, driven by expectations surrounding its AI-based regenerative medicine platform technology.

On the morning of the 24th, in the KOSDAQ market, Rokit Healthcare showed strong performance, trading at 48,000 won, up by the daily price limit. A surge in buying volume from the opening bell pushed the stock into the upper limit, and it maintained its upward trend throughout the session. Accompanied by massive trading volume, the company emerged as a key focus stock in the market that day.

■ Hyper-Personalized AI 3D Bioprinting Proves Efficacy in Real Clinical Settings

The market is closely watching the commercialization results of Rokit Healthcare's 'hyper-personalized AI 3D bioprinting regenerative medicine platform.'

According to the company, utilizing this technology to treat patients with intractable diabetic foot ulcers (DFU), burns, skin cancer, and traumatic wounds in real-world clinical settings around the globe resulted in a tissue regeneration success rate of 94.9% and an average treatment period of 7.7 weeks.

This data is particularly significant because it is based on long-term tracking of Real-World Evidence (RWE) accumulated in actual medical environments, rather than from short-term clinical trials or laboratory conditions. This is interpreted as simultaneously proving both the stability of the technology and its commercial viability.

■ Regenerative Medicine Market Growth... Expanding Interest in Related Stocks

The regenerative medicine market is continuously growing, driven by an aging population, the rise of chronic diseases, and expanding demand for personalized treatments. As next-generation regenerative medicine platforms combining AI and 3D bioprinting gain attention, investor interest in related companies is also growing.

The industry views the future expansion of regenerative medicine applications and successful entry into global markets as key variables that will determine corporate value.

[※ This article was written with AI assistance based on publicly available data and market information. The content included in this article is reference material for investment decisions and does not constitute a recommendation to buy or sell any specific stock, nor does it guarantee any profit. The stock market can fluctuate due to various factors, so investment decisions must be made based on the investor's own judgment and responsibility. As some information interpretation or errors may occur during the AI analysis process, please be sure to verify regulatory filings and corporate announcements before making a final investment.]